Loxo Oncology(LOXO)

汤诗语2018-06-05 11:01

非小细胞肺癌（NSCLC）的用药路径，红框表示诊断。看上去，未来用药非常依赖诊断，无论是化学方式还是基因测序方式。再结合之前讨论$Loxo Oncology, Inc. (LOXO)$ 时，也发现使用其RET抑制剂或TRK抑制剂也需要诊断，这样看，未来诊断可能是个很大的增量。查看全文

琳子的日复一日2018-06-05 00:45

$Loxo Oncology, Inc. (LOXO)$ 今天获利盘抛压超预期，更新下机构评级查看全文

an小安2018-06-04 23:51

$Deciphera医药(DCPH)$ $Loxo Oncology, Inc. (LOXO)$ 本届ASCO亮眼的两家。 $内克塔疗法(NKTR)$ 失意人查看全文

淘沙见金2018-06-04 09:21

ASCO周一投资者反应无责任预测： $内克塔疗法(NKTR)$ 跌， $bluebird bio(BLUE)$ 小跌，JNCE跌，BPMC小跌。 $Loxo Oncology, Inc. (LOXO)$ 小涨，ARRY小涨，DCPH 小涨查看全文

琳子的日复一日2018-06-03 11:03

$Loxo Oncology, Inc. (LOXO)$ 管线每一个都很强啊，值得长期持有的好票查看全文

群氓鄙陋2018-06-03 08:40

Mark LOXO $Loxo Oncology, Inc. (LOXO)$ 与竞争对手BPMC $Blueprint Medicines Corporation(BPMC)$ 非小细胞肺癌查看全文

LOXO-292-ASCO数据更新简析

淘沙见金2018-06-03 05:41

LOXO $Loxo Oncology, Inc. (LOXO)$ 在今天更新了RET靶向药LOXO-292临床一期的数据，具体数据如下：
针对NSCLC，反应率在77%。针对携带甲状腺髓质癌（Medullary thyroid cancer，简称MTC），反应率在45%。这个结果要略好于竞争对手BPMC $Blueprint Medicines Corporation(BPMC)$ 在AACR上公布...查看全文

黄建平2018-06-02 22:28

$Loxo Oncology, Inc. (LOXO)$ 这么小一个公司连续开发了两个效果逆天的首创靶点新药：NTRK、RET，为什么这么牛？查看全文

an小安2018-06-02 21:05

$Loxo Oncology, Inc. (LOXO)$ ASCO2018:LOXO-292数据
77% ORR in RET fusion+ pts (vs. 69% in abstract)很好的数据，等待更多细节网页链接查看全文

usbiostock2018-05-30 09:23

$Loxo Oncology, Inc. (LOXO)$ Larotrectinib治疗带有NTRK融合基因的成人和儿童局部进展或转移性实体瘤PDUFA日期：2018年11月26日。查看全文

$Loxo Oncology(LOXO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001140361-20-003307  Act: 34  Size: 10 KB 网页链接

$Loxo Oncology(LOXO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902219-20-000048  Act: 34  Size: 32 KB 网页链接

$Loxo Oncology(LOXO)$ 15-12B - Securities registration termination [Section 12(b)] Filed: 2019-02-25 AccNo: 0001193125-19-049296 Size: 10 KB 网页链接

$Loxo Oncology(LOXO)$ EFFECT - Notice of Effectiveness Filed: 2019-02-21 AccNo: 9999999995-19-000306 Size: 1 KB 网页链接

$Loxo Oncology(LOXO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-02-15 AccNo: 0000950142-19-000290 Size: 146 KB 网页链接

$Loxo Oncology(LOXO)$ POS AM - Post-Effective amendments for registration statement Filed: 2019-02-15 AccNo: 0001193125-19-042490 Size: 18 KB 网页链接

$Loxo Oncology(LOXO)$ POSASR - Post-effective Amendment to an automatic shelf registration statement Filed: 2019-02-15 AccNo: 0001193125-19-042498 Size: 18 KB 网页链接

$Loxo Oncology(LOXO)$ 8-K - Current report Filed: 2019-02-15 AccNo: 0001193125-19-042505 Size: 114 KBItem 2.01: Completion of Acquisition or Disposition of AssetsItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem...

$Loxo Oncology(LOXO)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-02-15 AccNo: 0001193125-19-042509 Size: 26 KB 网页链接

$Loxo Oncology(LOXO)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-02-15 AccNo: 0001193125-19-042519 Size: 26 KB 网页链接